717 related articles for article (PubMed ID: 31616443)
1. WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment.
Li X; Xiang Y; Li F; Yin C; Li B; Ke X
Front Immunol; 2019; 10():2293. PubMed ID: 31616443
[TBL] [Abstract][Full Text] [Related]
2. Intrinsic β-catenin signaling suppresses CD8
Xue J; Yu X; Xue L; Ge X; Zhao W; Peng W
Biomed Pharmacother; 2019 Jul; 115():108921. PubMed ID: 31078045
[TBL] [Abstract][Full Text] [Related]
3. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
Gajewski TF; Corrales L; Williams J; Horton B; Sivan A; Spranger S
Adv Exp Med Biol; 2017; 1036():19-31. PubMed ID: 29275462
[TBL] [Abstract][Full Text] [Related]
4. WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers.
Luke JJ; Bao R; Sweis RF; Spranger S; Gajewski TF
Clin Cancer Res; 2019 May; 25(10):3074-3083. PubMed ID: 30635339
[TBL] [Abstract][Full Text] [Related]
5. Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response.
Garris CS; Luke JJ
Clin Cancer Res; 2020 Aug; 26(15):3901-3907. PubMed ID: 32332013
[TBL] [Abstract][Full Text] [Related]
6. Targeting Wnt/β-Catenin Signaling for Cancer Immunotherapy.
Wang B; Tian T; Kalland KH; Ke X; Qu Y
Trends Pharmacol Sci; 2018 Jul; 39(7):648-658. PubMed ID: 29678298
[TBL] [Abstract][Full Text] [Related]
7. Wnt Signaling Cascade in Dendritic Cells and Regulation of Anti-tumor Immunity.
Suryawanshi A; Hussein MS; Prasad PD; Manicassamy S
Front Immunol; 2020; 11():122. PubMed ID: 32132993
[TBL] [Abstract][Full Text] [Related]
8. Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types.
Bao R; Stapor D; Luke JJ
Genome Med; 2020 Oct; 12(1):90. PubMed ID: 33106165
[TBL] [Abstract][Full Text] [Related]
9. Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
Wall JA; Meza-Perez S; Scalise CB; Katre A; Londoño AI; Turbitt WJ; Randall T; Norian LA; Arend RC
Gynecol Oncol; 2021 Jan; 160(1):285-294. PubMed ID: 33168307
[TBL] [Abstract][Full Text] [Related]
10. Wnt signaling pathway in cancer immunotherapy.
Zhou Y; Xu J; Luo H; Meng X; Chen M; Zhu D
Cancer Lett; 2022 Jan; 525():84-96. PubMed ID: 34740608
[TBL] [Abstract][Full Text] [Related]
11. Immune suppression and resistance mediated by constitutive activation of Wnt/β-catenin signaling in human melanoma cells.
Yaguchi T; Goto Y; Kido K; Mochimaru H; Sakurai T; Tsukamoto N; Kudo-Saito C; Fujita T; Sumimoto H; Kawakami Y
J Immunol; 2012 Sep; 189(5):2110-7. PubMed ID: 22815287
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody.
Katoh Y; Yaguchi T; Kubo A; Iwata T; Morii K; Kato D; Ohta S; Satomi R; Yamamoto Y; Oyamada Y; Ouchi K; Takahashi S; Ishioka C; Matoba R; Suematsu M; Kawakami Y
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793868
[TBL] [Abstract][Full Text] [Related]
13. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.
Spranger S; Bao R; Gajewski TF
Nature; 2015 Jul; 523(7559):231-5. PubMed ID: 25970248
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment.
Spranger S
Int Immunol; 2016 Aug; 28(8):383-91. PubMed ID: 26989092
[TBL] [Abstract][Full Text] [Related]
15. Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer.
Sweis RF; Spranger S; Bao R; Paner GP; Stadler WM; Steinberg G; Gajewski TF
Cancer Immunol Res; 2016 Jul; 4(7):563-8. PubMed ID: 27197067
[TBL] [Abstract][Full Text] [Related]
16. Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients.
Massi D; Romano E; Rulli E; Merelli B; Nassini R; De Logu F; Bieche I; Baroni G; Cattaneo L; Xue G; Mandalà M
Eur J Cancer; 2017 Jun; 78():70-81. PubMed ID: 28412591
[TBL] [Abstract][Full Text] [Related]
17. Blockade of β-Catenin-Induced CCL28 Suppresses Gastric Cancer Progression via Inhibition of Treg Cell Infiltration.
Ji L; Qian W; Gui L; Ji Z; Yin P; Lin GN; Wang Y; Ma B; Gao WQ
Cancer Res; 2020 May; 80(10):2004-2016. PubMed ID: 32156780
[TBL] [Abstract][Full Text] [Related]
18. Wnt/beta-catenin pathway: modulating anticancer immune response.
Pai SG; Carneiro BA; Mota JM; Costa R; Leite CA; Barroso-Sousa R; Kaplan JB; Chae YK; Giles FJ
J Hematol Oncol; 2017 May; 10(1):101. PubMed ID: 28476164
[TBL] [Abstract][Full Text] [Related]
19. WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses.
Mortezaee K
Clin Exp Med; 2024 Jan; 24(1):15. PubMed ID: 38280119
[TBL] [Abstract][Full Text] [Related]
20. Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape.
Takeuchi Y; Tanegashima T; Sato E; Irie T; Sai A; Itahashi K; Kumagai S; Tada Y; Togashi Y; Koyama S; Akbay EA; Karasaki T; Kataoka K; Funaki S; Shintani Y; Nagatomo I; Kida H; Ishii G; Miyoshi T; Aokage K; Kakimi K; Ogawa S; Okumura M; Eto M; Kumanogoh A; Tsuboi M; Nishikawa H
Sci Immunol; 2021 Nov; 6(65):eabc6424. PubMed ID: 34767457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
